Scarica l'app Stockscreener
46.78
0.15%
-0.102
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché BMY Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$46.88
Aprire:
$46.9
Volume 24 ore:
5.66M
Relative Volume:
0.42
Capitalizzazione di mercato:
$100.96B
Reddito:
$47.64B
Utile/perdita netta:
$5.42B
Rapporto P/E:
17.52
EPS:
2.67
Flusso di cassa netto:
$13.09B
1 W Prestazione:
-7.44%
1M Prestazione:
-12.90%
6M Prestazione:
-13.54%
1 anno Prestazione:
+4.62%
Intervallo 1D:
$46.70
$47.12
Intervallo di 1 settimana:
$46.52
$50.60
Portata 52W:
$39.35
$63.33
Bristol Myers Squibb Co Stock (BMY) Company Profile
Nome
Bristol Myers Squibb Co
Settore
Industria
Telefono
(609) 252-4621
Indirizzo
ROUTE 206 AND PROVINCE LINE ROAD, PRINCETON, NY
Confronta BMY con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BMY
Bristol Myers Squibb Co
|
46.72 | 100.96B | 47.64B | 5.42B | 13.09B | 2.67 |
|
LLY
Lilly Eli Co
|
745.01 | 674.93B | 49.00B | 11.11B | -1.27B | 12.29 |
|
JNJ
Johnson Johnson
|
154.44 | 370.90B | 89.33B | 21.81B | 18.57B | 8.99 |
|
ABBV
Abbvie Inc
|
186.71 | 342.01B | 57.37B | 4.20B | 17.83B | 2.35 |
|
NVO
Novo Nordisk Adr
|
66.22 | 291.20B | 42.09B | 14.65B | 10.11B | 3.2833 |
|
NVS
Novartis Ag Adr
|
109.26 | 219.89B | 53.22B | 12.86B | 14.85B | 6.39 |
Bristol Myers Squibb Co Stock (BMY) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-04-22 | Iniziato | Cantor Fitzgerald | Neutral |
| 2025-04-22 | Iniziato | Piper Sandler | Overweight |
| 2024-12-16 | Aggiornamento | Jefferies | Hold → Buy |
| 2024-12-10 | Ripresa | BofA Securities | Neutral |
| 2024-11-15 | Iniziato | Wolfe Research | Peer Perform |
| 2024-11-13 | Aggiornamento | Daiwa Securities | Neutral → Outperform |
| 2024-11-12 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2024-10-25 | Downgrade | Citigroup | Buy → Neutral |
| 2024-10-17 | Iniziato | Bernstein | Mkt Perform |
| 2024-07-29 | Downgrade | Barclays | Overweight → Equal Weight |
| 2024-03-11 | Downgrade | Societe Generale | Buy → Hold |
| 2024-02-06 | Downgrade | Redburn Atlantic | Buy → Neutral |
| 2024-01-03 | Downgrade | BofA Securities | Buy → Neutral |
| 2023-11-15 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2023-11-09 | Iniziato | Deutsche Bank | Hold |
| 2023-11-02 | Downgrade | Daiwa Securities | Outperform → Neutral |
| 2023-10-27 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2023-10-27 | Aggiornamento | HSBC Securities | Reduce → Hold |
| 2023-10-27 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2023-10-20 | Ripresa | UBS | Neutral |
| 2023-07-14 | Iniziato | HSBC Securities | Reduce |
| 2023-07-10 | Iniziato | SVB Securities | Market Perform |
| 2023-06-28 | Iniziato | Daiwa Securities | Outperform |
| 2023-03-06 | Iniziato | Jefferies | Hold |
| 2023-01-17 | Iniziato | Cantor Fitzgerald | Overweight |
| 2022-11-18 | Iniziato | Credit Suisse | Neutral |
| 2022-10-10 | Downgrade | Guggenheim | Buy → Neutral |
| 2022-09-14 | Downgrade | Berenberg | Buy → Hold |
| 2022-06-03 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2022-04-06 | Ripresa | Morgan Stanley | Underweight |
| 2021-12-17 | Iniziato | Goldman | Buy |
| 2021-12-09 | Ripresa | Wells Fargo | Equal Weight |
| 2021-11-19 | Iniziato | BMO Capital Markets | Outperform |
| 2021-11-01 | Downgrade | Argus | Buy → Hold |
| 2021-07-27 | Ripresa | Truist | Buy |
| 2021-04-30 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2021-04-13 | Aggiornamento | Truist | Hold → Buy |
| 2020-11-16 | Aggiornamento | Societe Generale | Hold → Buy |
| 2020-11-10 | Ripresa | Bernstein | Mkt Perform |
| 2020-11-06 | Downgrade | Gabelli & Co | Buy → Hold |
| 2020-10-19 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2020-09-29 | Iniziato | Berenberg | Buy |
| 2020-07-28 | Iniziato | Raymond James | Outperform |
| 2020-04-02 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2020-03-23 | Downgrade | Societe Generale | Buy → Hold |
| 2020-02-27 | Iniziato | Barclays | Equal Weight |
| 2020-01-06 | Ripresa | Citigroup | Buy |
| 2019-12-13 | Aggiornamento | Argus | Hold → Buy |
| 2019-11-22 | Ripresa | Morgan Stanley | Equal-Weight |
| 2019-10-17 | Ripresa | BofA/Merrill | Buy |
| 2019-08-14 | Aggiornamento | Atlantic Equities | Neutral → Overweight |
| 2019-05-28 | Iniziato | Goldman | Buy |
| 2019-05-20 | Downgrade | Argus | Buy → Hold |
| 2019-05-03 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2019-05-03 | Ripresa | JP Morgan | Overweight |
| 2019-01-15 | Aggiornamento | Societe Generale | Sell → Buy |
| 2018-10-22 | Downgrade | Citigroup | Buy → Neutral |
Mostra tutto
Bristol Myers Squibb Co Borsa (BMY) Ultime notizie
U.S. Small Business Association Awards Renaissance Global Services Two Prestigious Honors - GlobeNewswire Inc.
Neuroendocrine Tumor Treatment Market: Investment Analysis & - openPR.com
Bristol Myers Squibb Co. Becomes Oversold - Nasdaq
Bristol Myers Squibb Co. Named Top Dividend Stock With Insider Buying and 5.21% Yield (BMY) - Nasdaq
Urothelial Carcinoma Market on Track for Major Expansion by 2034, According to DelveInsight | Infinity, QED Therapeutics, BeiGene, Eli Lilly, Roche, UroGen, NektarTherapeutics, BMS, Incyte, Abbisko - Barchart.com
Improving Access to Care by Strengthening Local Health System Capacity - CSRwire
The Zacks Analyst Blog Highlights Verizon Communications, Bristol-Myers Squibb, Canadian Pacific and Nova LifeStyle - Yahoo Finance
2seventy bio Reports First Quarter Financial Results and Provides Update on Proposed Acquisition by Bristol Myers Squibb - BioSpace
Top Research Reports for Verizon Communications, Bristol-Myers Squibb & Canadian Pacific - MSN
Bristol Myers Squibb to Invest $40B in the U.S. - Contract Pharma
Advanced Renal Cell Carcinoma Market Predicted to See Upsurge Through 2034, Highlights DelveInsight | Pfizer, AbbVie, Bristol-Myers Squibb, Abbott, Takeda, Amgen, Novartis, AVEO Pharma, Calithera - The Globe and Mail
Multiple Myeloma Market Set to Grow Substantially Through 2034, DelveInsight Projects | Johnson & Johnson Innovative Medicine, Bristol Myers Squibb, Regeneron, AbbVie and Roche, Janssen Pharma - Barchart.com
Bristol Myers Squibb appoints new general counsel - | Governance Intelligence
Bristol Myers Squibb Co. stock underperforms Tuesday when compared to competitors - MSN
BMS Commits $40B over Five Years to U.S. R&D, Manufacturing - Genetic Engineering and Biotechnology News
Bristol-Myers GC Hands Over Legal Department To Successor - Law360
Bristol Myers Squibb names new executive vice president By Investing.com - Investing.com Canada
Bristol Myers (BMY) Experiences Increased Bearish Activity in Op - GuruFocus
Bristol Myers (BMY) Experiences Increased Bearish Activity in Options Market | BMY Stock News - GuruFocus
Bristol Myers (BMY) Unveils $40 Billion Investment in U.S. Over Five Years | BMY Stock News - GuruFocus
Bristol Myers Squibb Appoints Cari Gallman as EVP, General Counsel and Chief Policy Officer - citybiz
Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields - Benzinga
Bristol Myers (BMY) Appoints Cari Gallman as New General Counsel - GuruFocus
Bristol Myers Squibb’s injectable Opdivo formulation granted MHRA for solid tumours - PMLiVE
Bristol Myers Squibb announces $40bn US investment plan over five years - Yahoo Finance
Bristol Myers Squibb names new executive vice president - Investing.com
Bristol Myers Squibb Appoints Cari Gallman as Executive Vice President, General Counsel and Chief Policy Officer - Quantisnow
Bristol Myers to invest $40 billion in the US over 5 years | Business Information & News | FE - Westlaw Today
Bristol Myers to invest $40 billion in the US over 5 years - Reuters
Bristol Myers to invest $51.6 billion in the US over 5 years - The Straits Times
Company with deep NJ roots plans hundreds of more layoffs out of New Jersey - New Jersey 101.5
Bristol Myers to invest $40 billion in the US over 5 years, CEO says - marketscreener.com
Bristol Myers Promises $40 Billion US Investment Over Five Years - MSN
Bristol Myers Squibb Laying Off 500+ Employees From Lawrence Township Office - dailyvoice.com
Layoff Tracker: Pliant Cuts 45% of Staff To Extend Cash Runway - BioSpace
Was Jim Cramer Right About Bristol-Myers Squibb Company (BMY)? - Insider Monkey
Cari Gallman - Bristol Myers Squibb
Bristol-Myers Squibb (BMY) Faces Valuation Concerns - GuruFocus
Are Wall Street Analysts Bullish on Bristol-Myers Stock? - MSN
Jim Cramer Says He Likes Bristol-Myers Squibb (BMY) More Than Merck Due to Schizophrenia Drug - Insider Monkey
MHRA approval for BMS’ SC Opdivo - The Pharma Letter
Bristol-Myers Squibb's (NYSE:BMY) Strong Earnings Are Of Good Quality - Yahoo Finance
BMY Gains UK Approval for Faster Nivolumab Injection | BMY Stock News - GuruFocus
Piper Sandler Raises Price Target for Bristol Myers (BMY) to $66 | BMY Stock News - GuruFocus
Bristol Myers Squibb: innovating oncology care - MSN
Analysis of Cancer Immunotherapy Technologies and Global Markets to 2029 - GlobeNewswire Inc.
Is Bristol-Myers Squibb Company (BMY) the Best Long-Term Dividend Stock to Buy According to Billionaires? - Insider Monkey
BMY: Bristol Myers' Chief Medical Officer Acquires Additional Sh - GuruFocus
Here is What to Know Beyond Why Bristol Myers Squibb Company (BMY) is a Trending Stock - Yahoo Finance
Our impact - Bristol Myers Squibb
Jim Cramer is Recommending This Dividend Stock With 5% Yield for ‘Good Protection’ - Yahoo Finance
Bristol Myers Squibb Co Azioni (BMY) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.24%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):